Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Maine Endocrine Therapy Pri…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MainePolicy N/A

    Endocrine Therapy Prior Authorization Form — Breast Cancer Treatment and Risk Reduction

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Maine policy alerts

    Know when Blue Cross Blue Shield - Maine releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A provider-facing authorization form governing prior authorization requests for select endocrine therapies (anastrozole, exemestane, letrozole, raloxifene, Soltamox, tamoxifen) for Blue Cross Blue Shield - Maine members. It applies to requests for these drugs and documents required clinical information to determine coverage.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyEndocrine Therapy Prior Authorization Form — Breast Cancer Treatment and Risk Reduction
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the signed form with answers to the clinical questions to the Maine fax number to request prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7listed drug choices on form
    4explicit clinical questions
    1state-specific fax (ME)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Determination Criteria

    Clinical data required for coverage determination

    Coverage assessment is based on the following provider-confirmed clinical criteria collected on the form.

    Indication: Medication is being prescribed either to (A) a woman >35 years at increased risk for breast cancer (including prior atypia/LCIS or other risk factors such as BRCA1/2, prior chest radiation, or family history) OR (B) a woman with a current or prior diagnosis of breast cancer or ductal carcinoma in situ (DCIS)

    Collected via questions 1 and 2 on the form

    Agent-specific requirements

    • Raloxifene requirement: If Raloxifene is requested, patient must be post-menopausal

      Question 3

    • Soltamox requirement: If Soltamox (tamoxifen oral solution) is requested, patient must be unable to swallow or have difficulty swallowing tamoxifen tablets

      Question 4

    The form implies that certain agent-specific conditions must be met for coverage. Specifically, requests for Raloxifene must document that the patient is post-menopausal, and requests for Soltamox must document that the patient is unable to swallow or has difficulty swallowing tamoxifen tablets. If these agent-specific conditions are not affirmed on the form, the request may be considered outside the intended indications captured by this authorization form.

    Completion of the clinical questions is required to determine coverage. Absence of answers to the eligibility items — including whether the medication is for a woman aged >35 at increased risk, for current/prior breast cancer or DCIS, or the agent-specific menopause/swallowing items — may render the request not medically necessary or incomplete and subject the request to denial or additional information requests.

    Initial Authorization Requirements

    Initial authorization requirements

    Initial authorization relies on completion of the form questions confirming indication and relevant patient factors.

    Clinical indication provided: Provider must indicate whether the medication is for risk reduction in a woman >35 with increased risk OR for current/prior breast cancer or DCIS

    Questions 1 and 2 on the form

    Provider Submission & Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization submission — Complete the prior authorization request form with all clinical answers and the physician signature. Fax the fully completed form (do not include a cover sheet) to the payer contact for Maine: 844-474-3351 (fax) or 844-474-6221 (alternative). Ensure provider name, address, phone, requested drug selection, and signature/date are present.

    • Include selected drug: Anastrozole, Exemestane, Letrozole, Raloxifene, Soltamox, or Tamoxifen
    • Fax transmission: do not include a cover sheet
    Documentation Required

    Required Documentation

    Required documentation — The completed form must document the clinical indication(s) and eligibility criteria. Answer all checklist questions and provide supporting details in the clinical rationale area: diagnoses, relevant risk factors (e.g., atypical ductal/lobular hyperplasia, lobular carcinoma in situ, BRCA1/2, history of chest radiation, family history), prior history of breast cancer or DCIS, menopausal status when requesting Raloxifene, and swallowing ability if requesting Soltamox. Include any other diagnoses, symptoms, or pertinent clinical information.

    Key Definitions

    Increased breast cancer risk definition
    DefinitionWomen aged > 35 years with prior benign breast lesions (e.g., atypical ductal/lobular hyperplasia, lobular carcinoma in situ) and/or other risk factors (BRCA1/2 mutation, history of chest radiation therapy, or family history of breast cancer)
    Age criterionPatient older than 35 years
    Prior benign lesions examplesAtypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ (LCIS)
    Other risk factorsKnown BRCA1/BRCA2 mutation, prior chest radiation therapy, family history of breast cancer
    Source of determinationCollected via question 1 on the authorization form asking whether medication is for a woman >35 at increased risk

    Background

    This prior authorization form applies to endocrine agents used for breast cancer treatment or risk reduction, including Anastrozole, Exemestane, Letrozole, Raloxifene, Soltamox, and Tamoxifen. The form gathers whether the medication is being prescribed for a woman aged >35 at increased risk (for example, with prior atypia or LCIS, BRCA1/2, prior chest radiation, or family history) or for a patient with current or prior breast cancer/DCIS, and it includes specific items about post-menopausal status for raloxifene and swallowing ability for tamoxifen/Soltamox.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyEndocrine Therapy Prior Authorization Form — Breast Cancer Treatment and Risk Reduction
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the signed form with answers to the clinical questions to the Maine fax number to request prior authorization.
    SourceLink
    On This Page
    Coverage Determination CriteriaInitial Authorization RequirementsProvider Submission & Documentation RequirementsKey DefinitionsBackground
    • Document patient age (>35) when applicable
    • List specific risk factors (atypia, LCIS, BRCA, chest radiation, family history)
    • If Raloxifene: state patient is post‑menopausal
    • If Soltamox: document inability or difficulty swallowing tamoxifen tablets
    • Include physician signature and date
    Step Therapy

    Step Therapy

    Step therapy — There are no step therapy sequencing or drug‑step requirements specified on this form. Providers should still verify member plan rules for any additional plan‑level step edits before prescribing.

    • No drug‑step or sequencing required on this prior authorization form